Developer docs
API playgroundTry for free, no card

Search company profiles

Wellbeing Digital Sciences

Full company profile

uuid000ynet

Namestring
Wellbeing Digital Sciences
Legal namestring
Wellbeing Digital Sciences
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Wellbeing Digital Sciences is a Canadian for-profit wellness company, founded in 2017 and headquartered in Vancouver, British Columbia, focused on developing psychedelic-based medicines to treat mental illnesses. The company previously traded on the Canadian Securities Exchange under the ticker MEDI but is currently delisted. Its go-to-market centers on clinical-stage therapeutic development in the emerging psychedelic-medicine category, targeting indications in mental health.

In May 2021, the company acquired KGK Science, a contract research organization (CRO), which added in-house clinical research capabilities to support its therapeutic pipeline rather than relying on outsourced research services. The company is led by CEO Najla Guthrie and CFO Joe Ramelli, and is described as employing 51–100 staff consistent with a clinical-development-stage operating footprint.

Note on data discrepancy: the firm's website domain (wellbeingdigital.co) currently serves a Vietnamese-language sports-betting content platform branded Kèo Nhà Cái Tenisweb, which is inconsistent with the firm's stated psychedelic-medicine business and appears to reflect a domain collision or post-delisting repurposing rather than a corporate pivot. The analysis above is grounded in the firm's stated wellness/therapeutics identity and leadership disclosures.

Short descriptiontext

Wellbeing Digital Sciences is a Vancouver-based Canadian wellness company founded in 2017 developing psychedelic-based therapeutics for mental illness, with clinical research capabilities added via the 2021 acquisition of KGK Science; previously listed on CSE as MEDI but currently delisted.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
psychedelic medicine, mental health treatment, wellness therapeutics, clinical research services, contract research organization
Industry1 code
1Behavioral Health & Neurocognitive Therapeutics (Digital)
CodeHLACANAIPrimaryYes
NAICS code1 code
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Psychedelic Medicine and Mental Health Treatment
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Affiliate/Referral Revenue
TypeAffiliate Referral
Description

The platform aggregates betting odds information and match predictions, directing users to third-party betting platforms (Bong88, Net88, and numerous other online sportsbook operators) via referral/affiliate links, earning commissions for referred user sign-ups and deposits.

wellbeingdigital.co
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Wellbeing Digital Sciences is a Canadian wellness company focused on providing psychedelic medicines to treat mental illnesses. The company operates in the psychedelic-assisted therapy and mental health treatment space and expanded its capabilities by acquiring KGK Science in May 2021, a contract research organization that supports clinical research and scientific studies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 69% win rate cited as achievable with careful pre-match analysis
Product overview1 text field

Kèo Nhà Cái 5 / Tenisweb is a sports betting odds comparison and football analysis platform operated by Wellbeing Digital Sciences. The platform provides a comprehensive suite of sports information services including real-time live scores (Livescore), football match results (Kết quả bóng đá), expert match analysis and predictions (Nhận định bóng đá), league standings (Bảng xếp hạng), match schedules (Lịch thi đấu), and betting odds analysis (Soi Kèo). The platform aggregates odds from multiple bookmakers and covers football leagues worldwide including Premier League, La Liga, Serie A, Bundesliga, Ligue 1, Champions League, Europa League, V-League, World Cup, and Euro. The company operates under a digital media license and is based in Ha Long, Vietnam.

Product and service1 record
1Psychedelic Medicines for Mental Illness Treatment
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierPrimaryTypeGTM or Marketing Partner
Description

Bong88 is an online sports betting platform (online casino, sportsbook, lottery, poker). The site provides updated access links to Bong88 for users and serves as a referral partner, directing users to create accounts and bet on the Bong88 platform.

Strategic tierPrimaryTypeGTM or Marketing Partner
Description

Net88 is an online betting platform promoted on the site. The partnership involves providing Net88 access links and promotional banners, with users directed to Net88 for sports betting, casino, and lottery services.

Strategic tierSecondaryTypeGTM or Marketing Partner
Description

Online betting platform partner promoted via affiliate links and promotional banners on the Tenisweb platform. Users are directed to Gem88 for placing bets.

4Additional betting platforms (Big88, Keobongvip, Bin88, Fc88, Kong88, Bubet, Bomwin, Manclub, Soc88, Max88, Lucky88, Nhatvip, Fabet, Debet, Vip79, 11bet, One88, Oxbet, Nbet, Dabet, Five88, Xo88, Uk88, Sin88, May88, Zbet, Red88, Sv88, Win79, Hitclub)
Strategic tierMinorTypeGTM or Marketing Partner
Description

Numerous additional online betting platforms are promoted via affiliate links and promotional content on the site. Each platform is featured with placement links and promotional banners. The relationship involves directing platform users to sign up and bet with these partner platforms.

wellbeingdigital.co
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Psychedelic-therapy clinic operator and drug-development company formerly listed in Canada. Comparable peer in psychedelic therapy delivery for depression and anxiety.

TypeDirect peer
Description

Clinical-stage company developing mebufotenin (5-MeO-DMT) therapy for treatment-resistant depression. Comparable in psychedelic therapeutic modality and mental-health indication.

TypeDirect peer
Description

Psychedelic-therapeutics company developing deuterated psilocybin analogs for depression and anxiety disorders. Comparable peer in psychedelic drug development for mental-health indications.

TypeDirect peer
Description

Psychedelic-medicine developer working on LSD and psilocybin-based therapies for ADHD, anxiety, and depression. Closely comparable peer in psychedelic therapeutics targeting mental-health indications.

TypeDirect peer
Description

Canadian mental-health company offering psychedelic-assisted therapy services and clinical research infrastructure. Comparable in psychedelic-mental-health services and Canadian market presence.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing psychedelic and complementary mental-health therapies. Directly comparable in psychedelic-mental-health pipeline and platform model.

TypeDirect peer
Description

Clinical-stage psychedelic-medicine company developing psilocybin therapy for treatment-resistant depression. Directly comparable in therapeutic focus, regulatory pathway, and mental-health indication to Wellbeing Digital Sciences.

TypeDirect peer
Description

Canadian specialty-life-sciences company developing psilocybin-based therapeutics for mental-health and neurological indications. Comparable in psychedelic pipeline targeting mental illness.

TypeDirect peer
Description

Clinical-stage company developing next-generation 5-HT2A receptor agonists for neurological and mental-health disorders. Comparable peer in psychedelic-inspired drug development.

TypeDirect peer
Description

Canadian life-sciences company developing psychedelic-based therapeutics for mental-health conditions. Comparable peer in Canadian psychedelic drug-development space.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Wellbeing Digital Sciences

Psychedelic Medicine and Mental Health Treatmentwellbeingdigital.co

Wellbeing Digital Sciences is a Vancouver-based Canadian wellness company founded in 2017 developing psychedelic-based therapeutics for mental illness, with clinical research capabilities added via the 2021 acquisition of KGK Science; previously listed on CSE as MEDI but currently delisted.

What Wellbeing Digital Sciences does

Wellbeing Digital Sciences is a Canadian for-profit wellness company, founded in 2017 and headquartered in Vancouver, British Columbia, focused on developing psychedelic-based medicines to treat mental illnesses. The company previously traded on the Canadian Securities Exchange under the ticker MEDI but is currently delisted. Its go-to-market centers on clinical-stage therapeutic development in the emerging psychedelic-medicine category, targeting indications in mental health.

In May 2021, the company acquired KGK Science, a contract research organization (CRO), which added in-house clinical research capabilities to support its therapeutic pipeline rather than relying on outsourced research services. The company is led by CEO Najla Guthrie and CFO Joe Ramelli, and is described as employing 51–100 staff consistent with a clinical-development-stage operating footprint.

Note on data discrepancy: the firm's website domain (wellbeingdigital.co) currently serves a Vietnamese-language sports-betting content platform branded Kèo Nhà Cái Tenisweb, which is inconsistent with the firm's stated psychedelic-medicine business and appears to reflect a domain collision or post-delisting repurposing rather than a corporate pivot. The analysis above is grounded in the firm's stated wellness/therapeutics identity and leadership disclosures.

Wellbeing Digital Sciences firmographics

Firmographics
Name
Wellbeing Digital Sciences
Legal name
Wellbeing Digital Sciences
Website
https://wellbeingdigital.co
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
Wellbeing Digital Sciences is a Vancouver-based Canadian wellness company founded in 2017 developing psychedelic-based therapeutics for mental illness, with clinical research capabilities added via the 2021 acquisition of KGK Science; previously listed on CSE as MEDI but currently delisted.
Ownership category
akta.pro rank

Wellbeing Digital Sciences industry classification

Industry
Product category
Psychedelic Medicine and Mental Health Treatment
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

Keywords

  • Psychedelic medicine
  • Mental health treatment
  • Wellness therapeutics
  • Clinical research services
  • Contract research organization

Where Wellbeing Digital Sciences is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Wellbeing Digital Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Affiliate/Referral Revenue: The platform aggregates betting odds information and match predictions, directing users to third-party betting platforms (Bong88, Net88, and numerous other online sportsbook operators) via referral/affiliate links, earning commissions for referred user sign-ups and deposits.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Wellbeing Digital Sciences product offering

Product offering

Core offering

Wellbeing Digital Sciences is a Canadian wellness company focused on providing psychedelic medicines to treat mental illnesses. The company operates in the psychedelic-assisted therapy and mental health treatment space and expanded its capabilities by acquiring KGK Science in May 2021, a contract research organization that supports clinical research and scientific studies.

Product overview

Kèo Nhà Cái 5 / Tenisweb is a sports betting odds comparison and football analysis platform operated by Wellbeing Digital Sciences. The platform provides a comprehensive suite of sports information services including real-time live scores (Livescore), football match results (Kết quả bóng đá), expert match analysis and predictions (Nhận định bóng đá), league standings (Bảng xếp hạng), match schedules (Lịch thi đấu), and betting odds analysis (Soi Kèo). The platform aggregates odds from multiple bookmakers and covers football leagues worldwide including Premier League, La Liga, Serie A, Bundesliga, Ligue 1, Champions League, Europa League, V-League, World Cup, and Euro. The company operates under a digital media license and is based in Ha Long, Vietnam.

Differentiator

Problem solved

Functional benefit

Products and services

  • Psychedelic Medicines for Mental Illness Treatment

Quantifiable outcome

  • 69% win rate cited as achievable with careful pre-match analysis

Companies that use Wellbeing Digital Sciences

Customer profile

Segments1 record

Ideal customer profiles1 record

Wellbeing Digital Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Wellbeing Digital Sciences partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered primary, secondary and minor.

  • Bong88primaryGTM or Marketing PartnerBong88 is an online sports betting platform (online casino, sportsbook, lottery, poker). The site provides updated access links to Bong88 for users and serves as a referral partner, directing users to create accounts and bet on the Bong88 platform.
  • Net88primaryGTM or Marketing PartnerNet88 is an online betting platform promoted on the site. The partnership involves providing Net88 access links and promotional banners, with users directed to Net88 for sports betting, casino, and lottery services.
  • Gem88secondaryGTM or Marketing PartnerOnline betting platform partner promoted via affiliate links and promotional banners on the Tenisweb platform. Users are directed to Gem88 for placing bets.
  • Additional betting platforms (Big88, Keobongvip, Bin88, Fc88, Kong88, Bubet, Bomwin, Manclub, Soc88, Max88, Lucky88, Nhatvip, Fabet, Debet, Vip79, 11bet, One88, Oxbet, Nbet, Dabet, Five88, Xo88, Uk88, Sin88, May88, Zbet, Red88, Sv88, Win79, Hitclub)minorGTM or Marketing PartnerNumerous additional online betting platforms are promoted via affiliate links and promotional content on the site. Each platform is featured with placement links and promotional banners. The relationship involves directing platform users to sign up and bet with these partner platforms.

Scale indicators2 records

Recent moves3 records

Expansion highlights2 records

Wellbeing Digital Sciences competitors and assessment

Company assessment

Direct peers

  • Field Trip Health: Psychedelic-therapy clinic operator and drug-development company formerly listed in Canada. Comparable peer in psychedelic therapy delivery for depression and anxiety.
  • GH Research: Clinical-stage company developing mebufotenin (5-MeO-DMT) therapy for treatment-resistant depression. Comparable in psychedelic therapeutic modality and mental-health indication.
  • Cybin: Psychedelic-therapeutics company developing deuterated psilocybin analogs for depression and anxiety disorders. Comparable peer in psychedelic drug development for mental-health indications.
  • MindMed: Psychedelic-medicine developer working on LSD and psilocybin-based therapies for ADHD, anxiety, and depression. Closely comparable peer in psychedelic therapeutics targeting mental-health indications.
  • Numinus Wellness: Canadian mental-health company offering psychedelic-assisted therapy services and clinical research infrastructure. Comparable in psychedelic-mental-health services and Canadian market presence.
  • ATAI Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and complementary mental-health therapies. Directly comparable in psychedelic-mental-health pipeline and platform model.
  • Compass Pathways: Clinical-stage psychedelic-medicine company developing psilocybin therapy for treatment-resistant depression. Directly comparable in therapeutic focus, regulatory pathway, and mental-health indication to Wellbeing Digital Sciences.
  • Revive Therapeutics: Canadian specialty-life-sciences company developing psilocybin-based therapeutics for mental-health and neurological indications. Comparable in psychedelic pipeline targeting mental illness.
  • Bright Minds Biosciences: Clinical-stage company developing next-generation 5-HT2A receptor agonists for neurological and mental-health disorders. Comparable peer in psychedelic-inspired drug development.
  • BetterLife Pharma: Canadian life-sciences company developing psychedelic-based therapeutics for mental-health conditions. Comparable peer in Canadian psychedelic drug-development space.

Market position

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Wellbeing Digital Sciences social profiles

Digital presence

Wellbeing Digital Sciences compliance and trust

Trust signal

Compliance1 record

Wellbeing Digital Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Wellbeing Digital Sciences leadership team

Management profile

Number of profiles

Profiles2 records

Wellbeing Digital Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Wellbeing Digital Sciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wellbeing Digital Sciences

What does Wellbeing Digital Sciences do?

Wellbeing Digital Sciences is a Canadian wellness company focused on providing psychedelic medicines to treat mental illnesses. The company operates in the psychedelic-assisted therapy and mental health treatment space and expanded its capabilities by acquiring KGK Science in May 2021, a contract research organization that supports clinical research and scientific studies.

Is Wellbeing Digital Sciences a public or private company?

Wellbeing Digital Sciences is a private company. It is classified as unknown and is currently operating.

When was Wellbeing Digital Sciences founded?

Wellbeing Digital Sciences was founded in 2017. It employs 51 to 100 people.

Where is Wellbeing Digital Sciences based?

Wellbeing Digital Sciences is headquartered in Vancouver, Canada, in the North America region.

How does Wellbeing Digital Sciences make money?

One revenue line is on record: affiliate/Referral Revenue.

Who are Wellbeing Digital Sciences's main competitors?

Direct peers on record are Field Trip Health, GH Research, Cybin, MindMed, Numinus Wellness, ATAI Life Sciences, Compass Pathways, Revive Therapeutics, Bright Minds Biosciences and BetterLife Pharma.

Does Wellbeing Digital Sciences have an API?

No public API is recorded for Wellbeing Digital Sciences.

What industry is Wellbeing Digital Sciences in?

Wellbeing Digital Sciences's product category is Psychedelic Medicine and Mental Health Treatment. Its primary akta.pro industry code is HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital). Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogWellbeing Announces Definitive Agreement to Divest IRP HealthWellbeing Digital Sciences Inc. has entered into a definitive agreement for Pathway Health Corp. to acquire all or substantially all of the operating assets of its subsidiary, IRP Health Ltd. The transaction includes intellectual property, billing numbers, and equipment associated with IRP's multidisciplinary pain management and physical therapy programs serving military veterans and first responders in British Columbia. This divestment allows Wellbeing to refocus on expanding its mental health clinical network while enabling Pathway to broaden its services in pain and allied health.GlobeNewswireWellbeing Digital Sciences Inc. Changes Year-EndWellbeing Digital Sciences Inc. filed a notice to change its financial year-end from July 31 to October 31, per NI 51-102. The change, requested by auditors, creates a 15-month transitional year ending October 31, 2022. Further details will be filed on SEDAR.GlobeNewswireWellbeing Digital Sciences Announces the Appointment of Natalie Dolphin as VP of Marketing and Investment RelationsWellbeing Digital Sciences appointed Natalie Dolphin as VP of Marketing and Investment Relations, bringing over 15 years of experience in marketing and capital markets. She will oversee North American marketing and investment relations strategy, with a capital markets program planned over coming months.GlobeNewswireWellbeing Digital Sciences Announces Q3 Financial Results and Provides Corporate UpdateWellbeing Digital Sciences reported Q3 2022 results for the quarter ended April 30, 2022, with revenue of $5.28 million and a net loss of $21.15 million. The company also appointed Terry Zimaro as CFO and noted MindScape administered over 600 ketamine infusions. It plans to expand its clinical and digital acquisitions and evaluate capital market opportunities.GlobeNewswireWellbeing Digital Sciences Announces the Appointment ofWellbeing Digital Sciences appointed Terry Zimaro as Chief Financial Officer. Zimaro is a Chartered Professional Accountant with over 20 years of finance experience, specializing in high-growth environments and psychedelics. CEO Najla Guthrie said he will make an immediate impact on corporate strategy and growth.GlobeNewswireWellbeing Digital Sciences’ Dr. Corey Hilmas Invited to Participate as a Regulatory Panelist at Probiota Americas EventWellbeing Digital Sciences announced that Dr. Corey Hilmas will serve on a regulatory panel at the Probiota Americas event in Washington D.C. from June 1-3, 2022, alongside experts from Lallemand, FTC, and FDA. The company also approved a grant of 1,260,000 restricted share units to an affiliate consultant.GlobeNewswireWellbeing Digital Sciences Announces Resignation of Chief Financial OfficerWellbeing Digital Sciences announced the resignation of its Chief Financial Officer, Joseph Ramelli, who had joined in late 2021. The company expects to announce a new CFO appointment in the near future.GlobeNewswireWellbeing Digital Sciences Becomes a Founding Sponsor of the Women in Psychedelics NetworkWellbeing Digital Sciences became a founding sponsor of the Women in Psychedelics Network, led by CEO Najla Guthrie. The company also issued 5 million common shares and granted 210,000 restricted share units to a consultant. The network aims to build a community for women in the psychedelic industry.GlobeNewswireWellbeing Digital Sciences Welcomes Dr. Michael Ho as New Medical Director of MindScape Clinic in HoustonWellbeing Digital Sciences appointed Dr. Michael Ho as Medical Director of MindScape Ketamine & Infusion Therapy Clinic in Houston, effective May 2, 2022, replacing Dr. Quang Henderson. The clinic has administered over 600 low-dose ketamine infusions since being acquired in April 2021. Wellbeing is evaluating complementary mental health services and plans to grow its local patient base.GlobeNewswireWellbeing Digital Sciences Subsidiary IRP Health Approved as Part of Coveted Chronic Pain Centre of Excellence for Canadian Veterans NetworkIRP Health, a subsidiary of Wellbeing Digital Sciences, was approved as part of the Chronic Pain Centre of Excellence for Canadian veterans, with its Ottawa clinic approved to offer the Reactivation therapy program. The program is a 12-week interdisciplinary pain management initiative supported by CAD 20 million in VAC funding over five years.